(HAE) Haemonetics - Ratings and Ratios

Haemonetics Corporation (NYSE:HAE), a global leader in medical technology, specializes in blood management solutions. Their portfolio includes plasma collection systems like NexSys PCS and PCS2, which are complemented by donor management software such as NexLynk DMS and Donor360. These tools streamline operations for plasma donors and facilities. The company also offers blood component collection systems, including MCS brand apheresis equipment and BloodTrack software, enhancing blood management in healthcare settings. Hospital products include TEG and HAS hemostasis analyzers, supported by TEG Manager software for remote test monitoring. Additionally, Haemonetics provides Cell Saver Elite + for autologous blood recovery and VASCADE products for catheter-based clot formation. Their distribution network includes direct sales, independent distributors, and sales representatives.

Ticker Symbol: HAE Exchange: NYSE Type: common stock Country Origin: United States GICS Sub Industry: Health Care Supplies

Haemonetics Corporation is expected to maintain its position in the medical technology sector over the next quarter. Based on the provided data, here is the 3-month forecast:

- Average Volume 20d: 601,927 shares- Last Price: $62.64- SMA 20: $60.22- SMA 50: $63.13- SMA 200: $74.70- ATR: 2.23

- Market Cap: $2,872.08M USD- P/E: 22.51- P/E Forward: 11.43- P/B: 3.17- P/S: 2.09- RoE: 14.34

3-Month Forecast:

Technical Outlook:

• The stock is trading above its 20-day SMA, indicating support at current levels.
• The 50-day SMA is slightly above the current price, suggesting potential resistance.
• Average trading volume has remained steady, indicating stable investor interest.

Fundamental Outlook:

• The forward P/E ratio suggests investor expectations of future growth.
• Price-to-Book (P/B) ratio is at 3.17, suggesting the stock is trading at a premium.

Overall, Haemonetics is expected to experience stable performance with potential upside driven by earnings growth expectations.